Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285479 · ClinicalTrials.gov registry record
The Gilenya Pregnancy Registry
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 312
- Enrollment target
NCT01285479 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 312 participants.
The verdict
NCT01285479 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 312 participants
- Enrollment target
Study Summary
The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations.
Interventions
- DRUG Fingolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2011-10-15 |
| Est. Completion | 2024-05-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01285479
The ClinicalTrials.gov registry entry for NCT01285479 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fingolimod is the first listed.
NCT01285479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01285479 about?
NCT01285479 is a clinical study titled "The Gilenya Pregnancy Registry". The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and duri...
What is the current status of trial NCT01285479?
This trial is currently completed. The enrollment target is 312 participants. The study started on 2011-10-15. Estimated completion is 2024-05-29.
What interventions are being tested in trial NCT01285479?
The interventions under investigation include: Fingolimod (DRUG).
Who is sponsoring clinical trial NCT01285479?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.